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Original Article
Cell-surface Associated p43/Endothelial-monocyte-
activating-polypeptide-II in Hepatocellular Carcinoma
Cells Induces Apoptosis in T-lymphocytes
Wasek Faisal, Peter Symonds, Shiraj Panjwani, Yee Heng and John C. Murray, Wolfson Digestive 
Diseases Centre, University Hospital, University of Nottingham, Nottingham, UK.
OBJECTIVE: The novel, proinflammatory cytokine endothelial-monocyte-activating-polypeptide-II
(EMAP-II) was first found in tumour cell supernatants and is closely related or identical to the p43 com-
ponent of the mammalian multisynthetase complex. In its secreted form, EMAP-II has multiple cytokine-
like activities in vitro, including chemotactic, procoagulant and antiangiogenic properties. We recently
showed that neoplastic but not normal hepatocytes expresses the 34-kDa molecule on the cell surface 
in vitro and the cell-surface expression is upregulated by treatment with tumour necrosis factor (TNF)-α/
interferon (IFN)-γ and/or hypoxia. We hypothesized an immune-regulatory role of EMAP-II within neo-
plastic tissues and investigated its effects on lymphocytes.
METHODS: To study the role of EMAP-II in tumour cell-induced lymphocyte killing, Jurkat T-cells were
co-cultured with a range of hepatocellular carcinoma (HCC) cell monolayers (HuH-7, HepG2 and
Alexander cells), which were either untreated or treated with TNF-α/IFN-γ under normoxic and hypoxic
conditions over a period of 16–24 hours. Flow cytometric analysis of apoptosis in Jurkat cells was performed
using the annexin-V-FITC/propidium iodide technique.
RESULTS: rEMAP-II caused a dose-dependent apoptosis in Jurkat T-cells. Co-culture of Jurkat cells with
HCC cell monolayers induced significant apoptosis of the Jurkat cells. In general, under normoxic condi-
tions, cytokine-treated HCC cell monolayer caused more apoptosis than untreated cells. This effect was
enhanced by hypoxia. Critically, native EMAP-II expressed on the surface of the HCC cells also induced
activation of caspase-8 and apoptosis in Jurkat cells, which was partially but significantly blocked by addition
of polyclonal antibodies against EMAP-II to the incubation mixture.
CONCLUSION: Our data suggest that membrane-bound EMAP-II is cytotoxic to lymphocytes and,
therefore, might constitute a component of a novel, immunosuppressive pathway by which HCC cells may
eliminate attacking T-cells and evade the immune system. The mechanism by which it does so is currently
under investigation. [Asian J Surg 2007;30(1):13–22]
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Introduction
Endothelial-monocyte-activating-polypeptide-II (EMAP-
II) was initially isolated from the supernatant of cultured
murine tumour cells1 and was so named because of its
pleiotrophic activities towards endothelial cells, monocytes/
macrophages and neutrophils. The full functions of EMAP-
II in both normal and malignant tissues have yet to be
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determined, but it clearly has important roles in the medi-
ation of inflammatory response and coagulation. Purified
EMAP-II protein induces expression of E- and P-selectin
on endothelial cells in vitro, release of von-Willebrand factor,
chemotaxis of neutrophils and macrophages, and activa-
tion of neutrophil respiratory burst.2 In vivo, injection of
EMAP-II stimulates an inflammatory infiltrate in the mouse
footpad and some regression of implanted tumours.2,3
EMAP-II has also been implicated in lung morphogene-
sis,4 and has been shown to induce endothelial cell apop-
tosis and inhibit angiogenesis.5 On the basis of these
findings, EMAP-II has been described as a proinflammatory
cytokine with anti-angiogenic activity.
Full-length complementary deoxyribonucleic acids
(cDNAs) encoding human EMAP-II have been isolated2,6
and is consistent with a 34-kDa molecule of 328 amino
acid residues, which is proteolytically cleaved at a critical
aspartate residue (Asp144) to produce a smaller ∼20-kDa
polypeptide. One study shows that the 34-kDa molecule
is sensitive to cleavage by caspase-7,7 while other studies
suggest that other proteases may be more important.8,9
The p43 auxiliary component of the mammalian multi-
synthetase complex shares 86% and 85% amino acid iden-
tity with human and murine 34-kDa EMAP-II, respectively,
and the human p43 and EMAP-II are identical.10,11 It has
been suggested that a wide range of cultured cells, normal
and transformed, retain the 34-kDa form of p43/EMAP-II
in the cytoplasm while only some tumour cell lines release
fully or partially processed smaller forms of EMAP-II into
the culture medium, either constitutively, as a result of
cellular stress,12,13 or as a consequence of activation of
programmed cell death.14 This soluble form of EMAP-II
produced by some colorectal cancer cells has been shown
to induce apoptosis in activated lymphocytes.11,15
A recent immunohistochemical study of normal human
tissues suggested that tissues with high level of protein
synthesis and/or endocrine function are rich in EMAP-
II.11 Liver being an important organ for such functions,
we hypothesized that malignant transformation of hepa-
tocytes might cause overexpression of EMAP-II and studied
the regulation of expression of this molecule in hepato-
cellular carcinoma (HCC) cells, as it has not been looked
for before. We then sought a biological rationale for 
the expression of EMAP-II by the malignant hepatocytes,
other than acting as a chemoattractant for phagocytic
cells. If inflammatory cells were attracted into the tumour
microenvironment to clear cellular debris, a mechanism
to simultaneously inhibit the activity of tumour-specific
T-cells would be advantageous from a tumour perspec-
tive. We hypothesized that EMAP-II might therefore be
cytotoxic towards lymphocytes and tested this using cell
culture models of tumour–lymphocyte interaction.
Materials and methods
Cell lines and characterization of cells
The human leukaemic T-cell line Jurkat (clone E6.1), colorec-
tal adenocarcinoma cell line DLD-1, a normal hepatocyte
cell line THLE-3 and HCC cell lines PLC/Prf/5 (Alexander
cells) and HepG2 cells were all obtained from the American
Type Culture Collection (ATCC, Rockville, MD, USA) and
HuH-7 from Japanese Collection of Research Bioresources
(JCRB, Japan). All cell culture reagents and additives were
purchased from Sigma-Aldrich (Poole, UK) unless other-
wise stated. Flasks used to propagate THLE-3 cells were
coated (2 hours at 37°C) with 0.01 mg/mL bovine serum
albumin, 0.01 mg/mL fibronectin and 0.03 mg/mL colla-
gen I. THLE-3 cells were cultured in William’s media E
supplemented with bovine pituitary extract 50 μg/mL,
hydrocortisone 0.5 μg/mL, hEGF 0.5 ng/mL, transferrin
10 μg/mL, insulin 5 μg/mL, retinoic acid 1 × 10−4 ng/mL,
tri-iodothyronine 6.5 × 10−3 ng/mL and 70 ng/mL phos-
phoethanolamine. 100 U/mL penicillin–streptomycin solu-
tion, 4 nM L-glutamine and 10% heat inactivated fetal calf
serum (FCS) were also added to the basal media. DLD-1
cells were cultured in RPMI 1640 media supplemented
with 10% FCS and 100 U/mL penicillin–streptomycin.
Alexander cells, HuH-7, HepG2 and Jurkat cells were all
grown in Dulbecco’s minimum essential medium (DMEM)
with 10% FCS, 4 nM L-glutamine and 100 U/mL penicillin–
streptomycin. All cells were routinely grown in corning-
incorporated T-75 tissue culture flasks (Corning Inc., NY,
USA) and cultured in a humidified incubator at 37°C,
with 5% CO2, and routinely subcultured by removal from
flasks with 0.05% trypsin/1 mM ethylenediamine tetra-
acetic acid.
THLE-3, Alexander cells, HuH-7 and HepG2 were all
characterized for phenotypic characteristics of hepatocytes
using expression of albumin, alpha-fetoprotein (AFP),16
cytokeratin-1817 as positive markers by reverse transcriptase–
polymerase chain reaction, Western blotting and fluores-
cent microscopy and uptake of indocyanine green (ICG)
by spectrophotometric analysis.18 All cells strongly expressed
albumin and cytokeratin-18 and showed high absorbance
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for ICG uptake at 800 nm; all cells except THLE-3 also
expressed AFP (data not shown).
Antibodies (Abs) and recombinant proteins
Rabbit polyclonal Abs against EMAP-II (Bio-Source Intl.,
CA, USA) or in-house (R2B2) were used for immuno-
histochemistry, Western blotting and flow cytometry in
this study. The characteristics of the Abs, which recognize
the 34- and 20-kDa, as well as several intermediate forms
of EMAP-II, have been described elsewhere.7,9,13 Horseradish
peroxidase (HRP)- and fluorescein isothiocyanate (FITC)-
labelled anti-rabbit IgG Abs (DAKO, Glostrup, Denmark)
were used for detection of primary Abs. Recombinant
human tumour necrosis factor (TNF)-α and interferon
(IFN)-γ were obtained from PeproTech (London, UK).
Immunohistochemistry
Immunohistochemistry was performed on formalin fixed,
paraffin-embedded specimens of normal and HCC affected
human liver tissue for EMAP-II expression. Slides were
dewaxed in histolene, before being rehydrated in graded
ethanol solutions (100% to 30%). Antigen retrieval was
performed by boiling the slides for 10 minutes in citrate
buffer (10 mM citric acid, 25 mM NaOH). Slides were
blocked with normal goat serum for 20 minutes. EMAP-
II was identified by incubating the slides with purified
polyclonal anti-EMAP-II Abs (1 μg/mL in phosphate
buffered saline [PBS]) for 1 hour at room temperature.
Secondary detection was performed using Vectastain Elite
Kit, according to the manufacturer’s instruction (Vector
Laboratories, Burlingame, CA, USA). Slides were counter-
stained with haematoxylin solution (Vector Laboratories),
dehydrated in ethanol, and mounted with depex poly-
styrene solution (BDH, Poole, UK).
Detection of EMAP-II by Western blotting
Western blotting was conducted essentially as previously
described.7 Briefly, cells were trypsinized and washed with
cold PBS, counted and 5 × 106 cells were lysed in 400 μL
sodium dodecyl sulfate (SDS) buffer (0.5 M Tris-HCl, 10%
glycerol, 10% w/v SDS, 2% 2-ME, 0.1% bromophenol
blue). Supernatant proteins were precipitated with ice-
cold acetone and resuspended in 400 μL SDS buffer.
Samples were boiled for 10 minutes, total protein assay of
the samples was performed using Bio-Rad (Bio-Rad, CA,
USA) reagents and protocol and equal amount of total pro-
tein of different samples was loaded for electrophoresis
by SDS-PAGE (polyacrylamide gel electrophoresis) on
10% gels, and transferred onto nitrocellulose membranes
(Amersham, Bucks, UK). Membranes were blocked over-
night with 5% non-fat dried milk in 0.5% Tween 20/PBS,
and exposed to anti-EMAP-II Abs, diluted in blocking
solution for 2 hours at room temperature. Proteins were
visualized with HRP-conjugated goat anti-rabbit IgG
using the ECL system (Amersham).
Flow cytometric analysis of cell surface 
expression of EMAP-II
The expression of EMAP-II on the external membranes 
of hepatocytes was determined by flow cytometry. Cells
were incubated in DMEM with or without 20 ng/mL
TNF-α/IFN-γ in normoxia or hypoxia for 24 hours. After
removal of the medium, cells were harvested without
trypsin to reduce membrane damage, and fixed in 0.25%
glutaraldehyde/PBS for 10 minutes to restrict access of Abs
to cell surface antigens only. Cells were washed in PBS and
incubated with anti-EMAP-II polyclonal antibody (R2B2)
1 μg/mL for 2 hours. Surface EMAP-II expression was
detected by subsequent incubation with FITC-conjugated
secondary Abs (Sigma-Aldrich) for 30 minutes. Additional
cell samples were incubated with the secondary FITC-
conjugated Ab, but without primary Ab, as controls. The
cells were immediately analysed by flow cytometry. A total
of 20,000 events were stored for each sample.
Assessment of apoptosis by FITC-labelled 
annexin-V and propidium iodide (PI)
Annexin-V binds to phosphatidylserine (PS) exposed on
the external surface of the plasma membrane during the
early phase of the apoptotic programme, while DNA within
the nucleus only becomes accessible to PI during late apop-
tosis. Healthy living cells should therefore bind to neither
of these dyes, and these two reagents can be used together
to distinguish early and late apoptosis. The POPTEST™-
FITC (DAKO) employs the property of annexin V-FITC to
bind to PS in the presence of Ca2+. Jurkat cells, following
treatment with either tumour-conditioned media, recom-
binant EMAP-II or after co-culture with hepatocyte mono-
layers, were assessed for apoptosis. Untreated control cells
and cells treated with 20 ng/mL of TNF-α/IFN-γ were also
prepared. Samples were analysed in accordance with the
manufacturer’s protocol. Briefly, the cells of interest (i.e.
Jurkat cells) were washed with ice-cold culture medium
and finally suspended in ice-cold diluted binding buffer at
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105–106 cells/mL. One microlitre of annexin V-FITC and
2.5 μL of PI were added to each cell sample and left on ice
in the dark for 10 minutes. The samples were immediately
analysed using a Becton Dickenson FACScan, using the
LYSIS II programme. Analysis was restricted to the lympho-
cyte population by gating on forward and right angle scat-
ter. A total of 10,000 events were acquired for each analysis.
Caspase-8 assay
A colorimetric assay based on the specific cleavage of the
peptide substrate Ile-Glu-Thr-Asp-p-nitroanilide (IETD-
pNA) by active caspase-8, releasing pNA, was used as directed
by the manufacturer (Bio-Source). Active caspase-8 activity
was measured in extracts of control Jurkat cells, cells co-
cultured over a period of 12–24 hours with hepatocytes
untreated or treated with 20 ng/mL of TNF-α/IFN-γ in
the presence or absence or anti-EMAP-II Abs.
Conditioned medium and co-culture experiments
All adherent cell monolayers (THLE-3, DLD-1, Alexander,
HepG2 and HuH-7) were grown for 48 hours in serum-
free medium, in medium supplemented with TNF-α/
IFN-γ (20 ng/mL each), or in medium under hypoxic con-
ditions (∼1–2% O2). Used culture medium was centrifuged
at 2,000g for 5 minutes to remove cellular debris and
stored at −80°C. Jurkat cells were pelleted, resuspended in
conditioned medium and grown in normoxia or hypoxia
for 48 hours before analysing for apoptosis by the annexin-
V/PI method, as described previously. In co-culture experi-
ments, cells were grown up to 50–60% confluence. Cell
monolayers were then treated with TNF-α/IFN-γ (20 ng/
mL each) for 24 hours in normoxia or hypoxia. The media
were then removed, cell monolayer washed with PBS and
Jurkat cells (4 × 106) were co-cultured with the adherent
monolayer for 24 hours. Before addition of Jurkat cells,
some monolayers were treated with 10 μg/mL of anti-
EMAP-II Ab for 1 hour. Functional blocking of EMAP-II
with this concentration of R2B2 antibody has previously
been demonstrated.6 After 24 hours, the Jurkat cells were
removed and centrifuged at 500g for 5 minutes, and then
resuspended in PBS. Samples were analysed using the
annexin-V/PI technique described previously.
Statistical analysis
Analysis of FACScan data was performed using WinMDI
software 2.8 (TSRI Cytometry, La Jolla, CA, USA). Quanti-
tative analysis of positive immunohistochemical staining
for EMAP-II was done using the Simple PCI image analysis
software (version 5.1.0.0110, Cranberry Township PA, USA).
Student’s t test and one-way analysis of variance was used
where appropriate for testing the significance of the data.
All statistical tests were performed using SPSS (SPSS Inc.,
Chicago, IL, USA) and a p value of ≤ 0.05 was considered
significant. All experiments were performed in triplicates
and data shown are mean ± standard deviation.
Results
Expression of EMAP-II in normal and 
malignant human liver in vivo
Initially, we studied the expression of EMAP-II in archival
specimens of normal and HCC liver samples by immuno-
histochemistry. In general, hepatocytes in tissue sections
showed strong cytoplasmic immunoreactivity for EMAP-
II with a punctate pattern (Figure 1A), while the Kupffer
cells and bile ductules were generally negative. EMAP-II
staining appeared generally more intense within the hepa-
tocytes closer to the central vein, an observation that was
subsequently confirmed by image analysis. There was sig-
nificant gradual increase in expression of the polypeptide
from zone 1 to 3 of hepatic acini (p < 0.005) (Figure 1B).
This pattern of expression was lost in HCC, where the
malignant parenchymal cells showed an increased, wide-
spread and generalized staining, while the stromal cells
were still negative (Figure 1C).
Expression of EMAP-II in normal and 
malignant hepatocytes in vitro
We then examined expression of EMAP-II in a range of
cell lines derived from HCC and normal liver, to deter-
mine whether expression persisted in vitro, and whether
these cells retained EMAP-II within the cell, or released it
into the culture medium. Figure 2 shows a Western blot
of extracts from DLD-1 (colorectal carcinoma), THLE-3,
Alexander and HuH-7 cells and supernatant. All the cell
lines expressed EMAP-II within the cell, predominantly in
the 34-kDa form (lanes 1, 3, 5 and 7). In contrast to colorectal
carcinoma conditioned medium that contained detectable
levels of soluble EMAP-II (lane 2) none of the hepatocyte
cell lines secreted any EMAP-II in the culture medium
(lanes 4, 6 and 8).
The expression of EMAP-II on the surface of membrane-
stabilized hepatocyte cell lines under normoxic and hypoxic
conditions was then studied by flow cytometry using
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R2B2 polyclonal Abs (Figure 3). THLE-3 cells did not
express any EMAP-II on the cell surface under normoxic
or hypoxic conditions. A small proportion of Alexander
cells expressed surface EMAP-II when grown under nor-
moxic conditions but demonstrated a four- to fivefold
increase in surface EMAP-II when exposed to hypoxia.
HuH-7 cells expressed EMAP-II on the cell surface under
normal condition and showed about twofold increase in
surface expression under hypoxic conditions. Treatment
with the combination of TNF-α/IFN-γ caused a further
two- to threefold increase in mean fluorescence (data not
shown).
Cell surface-associated EMAP-II induces 
apoptosis in Jurkat cells
As demonstrated above, malignant but not normal hepa-
tocytes express EMAP-II on the cell surface, although they
do not release this protein into the medium. Because the
co-culture model does not require previously conditioned
medium, the hepatocytes can be exposed to cytokines to
stimulate EMAP-II expression, and the medium exchanged
before co-culturing with Jurkat cells. Therefore, at no time
are the target Jurkat cells exposed to exogenous cytokines,
and the subsequent killing of Jurkats may be attributed
to the inductive influence of the cytokines on the hepato-
cytes. Figure 4 shows a representative flow cytometric
analysis of apoptosis in target Jurkat cells following 
16-hour co-culture with untreated or treated (with TNF-α/
IFN-γ) Alexander and HuH-7 cells. As expected, both the
cell lines induced apoptosis in Jurkat cells and the treated
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Figure 1. (A) Immunohistochemistry of normal human liver shows
the expression of endothelial-monocyte-activating-polypeptide-II
(EMAP-II) (arrows) within hepatocytes. Note that EMAP-II is
expressed more in cells closer to the central vein. (B) Graph shows
data from image analysis demonstrating progressive increase in
the expression of EMAP-II from zone 1 to 3 in hepatic acinus
(n = 24, p < 0.005). (C) Immunohistochemistry of hepatocellular
carcinoma shows strong immunoreactivity against EMAP-II in
parenchymal cells. Note that the endothelial cells and bile ductules
also show positivity, while the stroma is generally negative.
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Figure 2. Colorectal carcinoma cells, hepatocellular carcinoma
and normal hepatocytes express endothelial-monocyte-activating-
polypeptide-II (EMAP-II) in vitro. Western blot of extracts of differ-
ent cells and supernatant, using anti-EMAP-II antibody. Lane 1 =
DLD-1 cell extract; lane 2 = DLD-1 supernatant; lane 3 = THLE-3
cell extract; lane 4 = THLE-3 supernatant; lane 5 = Alexander cell
extract; lane 6 = Alexander supernatant; lane 7 = HuH-7 cell
extract; lane 8 = HuH-7 supernatant.
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Figure 3. Malignant but not normal hepatocytes express endothelial-
monocyte-activating-polypeptide-II (EMAP-II) on the cell surface. Cells
were grown in either normoxia (dotted) or hypoxia (dash-dotted)
for 24 hours and incubated with R2B2 antibodies against EMAP-II;
negative controls were cells without primary antibodies.
cells induced more cell death in Jurkats than untreated
ones. Figure 5 shows a graph from pooled data indicating
that malignant hepatocytes induce significant apopto-
sis in Jurkat cells compared to media alone or normal
hepatocytes. However, none of the HCC cell-conditioned
media induce any significant apoptosis in Jurkat cells
compared to the controls (data not shown).
To demonstrate that at least part of the apoptosis
induced in Jurkat cells by the hepatocytes is attributable
to EMAP-II, co-culture experiments were carried out with
or without blocking concentrations of anti-EMAP-II Abs.
As shown in Figure 6, there was significant inhibition 
of apoptosis in Jurkat cells by HepG2 cells when co-
cultured with anti-EMAP-II Ab, while normal hepatocytes
did not induce any apoptosis by EMAP-II dependent
manner.
Activation of caspase-8 in hepatocyte-induced 
apoptosis of Jurkat cells
Caspase-8 is a member of interleukin-1β (IL-1β) converting
enzyme family of cysteine proteases (caspases). It is the
most upstream caspase in the CD95 apoptotic pathway.
Caspase-8 provides a direct link between cell-death receptors
and caspases. Uninduced Jurkat cells and cells co-cultured
with THLE-3 showed very low activity of caspase-8, while
cells co-cultured with all three malignant hepatocyte cell-
lines showed four- to sixfold increase in caspase-8 activity
over a period of 12–24 hours (Figure 7).
Effect of hypoxia on expression of cell-surface EMAP-II 
and its implication on Jurkat cell apoptosis
Under normoxic conditions, the malignant but not the
normal hepatocytes expressed EMAP-II on the cell surface.
The surface expression was upregulated by exposure of
the cells to hypoxia over a period of 16–24 hours (Figure
3). But our Western blot analysis of cell extracts from cells
grown under different conditions failed to show any true
upregulation of the protein (data not shown), which implies
that hypoxia causes an increased membrane translocation
of EMAP-II in malignant cells rather than increases protein
synthesis per se. Subsequently, when cells grown under
hypoxia were co-cultured with Jurkat cells, they induced
more apoptosis than cells grown under normoxia in an
EMAP-II dependent manner, as expected (Figure 4E/F).
Discussion
Tumour cells must develop strategies to avoid clearance
by the immune system to survive, expand their popula-
tions and metastasize. The process by which unwanted
tumour cells are cleared involves recognition of the altered
nature of the cell by the immune system followed by its
effective killing and elimination. Thus, tumour cells may
escape immune clearance by a diversity of mechanisms
including altering immune recognition or by modulation
of the cytotoxic response. The recent identification of the
Fas receptor (Fas, APO-1/CD95) and its ligand (FasL,
CD95L) as a major regulator of both apoptosis and immune
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Figure 4. Cell surface-associated endothelial-monocyte-activating-polypeptide-II induces apoptosis in Jurkat cells. (A, B) Cells were
co-cultured with either untreated Alexander or HuH-7 cells in normoxia; (C, D) tumour necrosis factor-α/interferon-γ treated cells in
normoxia or (E, F) treated cells in hypoxia and analysed by flow cytometry using the annexin-V/propidium iodide technique. Cells in
the right lower and upper quadrants are early and late apoptotic, respectively.
30
0
5
Media
alone
rEMAP-II
(10 nM)
THLE-3
Co-culture condition/cell-type
Alex. HuH-7 HepG2
10
A
po
pt
ot
ic
 Ju
rk
at
 c
el
ls
 (
%
)
15
20
25
*
†
‡
Figure 5. Hepatocellular carcinoma (HCC) cells but not normal hepatocytes induce apoptosis in Jurkat cells in co-culture. Jurkat
cells were co-cultured with normal hepatocytes or HCC cells or in media alone for 24 hours and then assessed for apoptosis using
flow cytometry. *p = 0.1; †p = 0.03; ‡p = 0.005.
function has provided insight into a range of attractive
mechanisms by which tumours escape from immune
clearance.19 In HCC, partial or complete loss of Fas
expression has been detected, and this loss is supposed to
result in reduced sensitivity of the tumour cells towards
T-cell toxicity.20,21 Furthermore, HCC cells have been
shown to generate soluble Fas (sFas) to antagonize FasL
killing by activated lymphocytes.21 Here, we report a novel
mechanism employed by HCC cells to evade the immune
response directed towards them.
Our initial experiments demonstrated that normal
human liver expresses EMAP-II within the cytoplasm 
in vivo. The compartmentalized pattern of distribution 
of EMAP-II in hepatic acini may be an extension of the
physiological property of the liver, which sequesters more
enzymes and cytokines in zone 3 than zone 1, or might be
a response to differing levels of oxygen tension in differ-
ent zones. However, this pattern of expression was not
seen in HCC, which showed an increased expression of
EMAP-II in a more generalized and widespread fashion.
Subsequently, we demonstrated by Western blotting
that the EMAP-II expression persisted in vitro in both nor-
mal and malignant hepatocytes. This is consistent with
our hypothesis that all human cells, both normal and
malignant, express the 34-kDa form of EMAP-II intracel-
lularly as part of multisynthetase complex in the form of
p43, but is only processed and released under certain con-
ditions, malignant transformation being one of them.
Unlike some colorectal cell lines, which secrete soluble
form of EMAP-II in the culture medium, HCC cells did
not produce any detectable soluble forms of EMAP-II.
Rather, they expressed EMAP-II on the cell surface, which
was further upregulated by treatment with TNF-α/IFN-γ
and/or hypoxia. Since hypoxia or regions of low oxygen
tension is a physiological component of the tumour micro-
environment, this observation strongly suggests the pos-
sibility of increased EMAP-II expression by malignant cells.
As Western blots of washed cell extracts only demonstrated
the 34-kDa form, it would appear that this is likely to be
the major form associated with the external membrane.
The immunohistochemistry result in conjunction
with the flow cytometric data showing increased surface
upregulation of EMAP-II in HCC cells under different
stimulation implies that the increased surface expression
of EMAP-II does not result from an increased synthesis of
EMAP-II per se, but is rather a membrane translocation
phenomenon, which would explain why we could not
detect any increased EMAP-II in HCC cells by Western
blotting.
The cell surface expression of EMAP-II subsequently
induced significant apoptosis in activated lymphocytes,
which could be significantly inhibited by anti-EMAP-II
Abs, as measured by the annexin-V/PI assay. Normal hepa-
tocytes, which did not express surface EMAP-II, were not
toxic to Jurkat cells, confirming our initial hypothesis.
This is the first demonstration of biological activity of
cell surface-associated EMAP-II in HCC cells, about which
very little is known. The mechanism by which EMAP-II is
translocated from inside the cell to the cell membrane is
also unknown. The EMAP-II precursor lacks a hydrophobic
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Figure 6. Significant inhibition of apoptosis of Jurkat cells by
malignant but not normal hepatocytes when co-cultured with
anti-endothelial-monocyte-activating-polypeptide-II antibody,
as assessed by the annexin-V/propidium iodide method.
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signal peptide necessary for membrane translocation, 
nor is it predicted to be glycosyl phosphatidylinositol
anchored. It has been suggested that the mature protein
is secreted via a novel pathway, in a similar manner to the
leaderless precursor of IL-1β, which is now known to be
shed initially in the form of membrane microvesicles.22
Our data suggest that besides the soluble form of EMAP-
II, surface expression alone and subsequent cell–cell con-
tact may be sufficient to render EMAP-II active against
lymphocytes.
The mechanism by which EMAP-II induces apoptosis
is poorly understood; however, our data, demonstrating
activation of caspase-8 in Jurkat cells following co-culture
with HCC cells, strongly implicate a death receptor path-
way in apoptosis initiated by EMAP-II. Berger et al5 have
shown that EMAP-II upregulates the expression of TNF-
R1 (p55) on endothelial cells in vitro. TNF-R1 and Fas,
both members of the TNF receptor family, are believed 
to be primary receptors for the initiation of death signals
in lymphocytes.23 The Jurkat cell clone (E6.1) used in 
our experiments expresses very little FasL on the surface.
Furthermore, we recently demonstrated activation of
phospho-p38 in this clone of Jurkat cells treated with
recombinant EMAP-II, which suggests that EMAP-II might
be involved in the initiation of apoptosis via the TNF-R1
mediated pathway (Symonds et al, unpublished data).
Therefore, this protein could be acting directly through
death receptor, which would group it with TNF, FasL and
TNF-related apoptosis-inducing ligands, or it could be
inducing or potentiating one of these death ligand/receptor
interactions.
Involvement of EMAP-II in viral brain disease in rats
with Borna disease virus has been evaluated and a signifi-
cant positive correlation between EMAP-II expression in
ramified microglial cells and viral load in different brain
regions has been demonstrated.24 In light of the fact that
HCC develops on top of chronic liver disease and viral
hepatitis, it would be interesting to study if viral hepatitis
and chronic liver disease cause an overexpression of
EMAP-II in the liver and whether it has any implications
in chronic viral subversion of the immune system leading
to eventual hepatocellular carcinogenesis.
The emerging experimental and clinicopathological
evidence indicates an important role of defensive strate-
gies aimed at avoiding immune-detection by tumour-
infiltrating lymphocytes as a means of immune escape 
in hepatocellular cancer. Although the mechanism of
EMAP-II-induced apoptosis remains unclear, it is appar-
ent that EMAP-II constitutes a novel component by which
tumour cells eliminate attacking T-cells and evade the
immune system. Translating this knowledge to clinical
practice may eventually prove valuable in developing
rational immune-based therapies for HCC.
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